IMV Inc. (IMV) Names Kyle Kuvalanka to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
IMV Appoints Kyle Kuvalanka to Board of Directors
March 25, 2021 7:05 AM EDTIMV to leverage Mr. Kuvalankas industry expertise as it advances its lead immunotherapy toward potential registration and commercialization
Company advancing novel immunotherapies in oncology and infectious diseases built on its proprietary DPX platform with novel lipid-based delivery technology
Wayne Pisano to retire after 10 years as a Board member
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the... More
